Mind the gap: what the UK's life sciences data tells us
What does recent data tell us about the UK’s life science sector?
At first glance, the government’s latest life sciences competitiveness datais a celebration of the sector’s strengths, but scratch beneath the surface and you might see some worrying signs.
Life science sector headlines in 2025 were stark to say the least.
Major pharma projects worth nearly £2bn were pulled and the industry is still wrestling with the question of whether it was a temporary blip, or something more structural.
Giving a retrospective look back, the Office For Life Science’s 2026 Competitiveness Indicators, which benchmarks the UK's performance across research, investment, clinical trials and skills against our international counterparts, sheds more light.
The results are in and they’re mixed.
The good
It shows Britain is still holding strong as a scientific heavyweight. Health R&D spending remains among the highest globally, with the UK maintaining the UK’s position among the top global destinations for venture funding, behind the United States and China.
The country remains a genuine powerhouse for generating ideas, intellectual property and early-stage companies.
There are also encouraging signs of recovery when it comes to investor confidence. VC investment closed 2025 at £3.37bn which, while down 12% on the previous year, still outperforms pre-pandemic norms. Equity finance bounced back in 2024, rising 32% to £4.5 billion, maintaining the UK’s position among the top global destinations for venture funding, behind the US and China
A signal of greater confidence, perhaps?
The bad
It seems that the clearest blip on the sector's health record is that of bench-to-bedside translation.
The data shows we rank last among the slowest of our international peers when it comes to clinical trials moving from approvals to patients. We have a system that excels at discovery but struggles when it comes to converting breakthroughs into treatments, successful companies or meaningful patient outcomes.
Since 2018, UK pharmaceutical R&D investment has lagged behind global growth trends, including a fall of around £100 million in 2023. Foreign direct investment into UK life sciences was around 58% lower in 2023 than in 2017, with the UK's ranking dropping from second to seventh over the same period.
Delays in trial setup, fragmented systems and talent constraints continue to slow progress.
The ugly
It’s an impact being felt well beyond the lab. Only 65% of newly approved medicines reach patients in England, (fewer still in Scotland), placing the UK behind our counterparts.
Scaling our ideas remains a further weak point. Despite having strong research foundations and improved funding, too few British firms are making the leap from promising science to global businesses.
It is a pattern the government has acknowledged. As Innovate UK's newly published strategy puts it: "The UK excels at making discoveries, generating intellectual property, spinning out and starting up. Yet when it comes to scaling, too many innovative businesses fail, stall or move overseas."
A missing link?
The gap between our scientific clout and real-world impact is well documented, but what the competitiveness data overlooks is the root cause and how to close it.
Innovate UK's prospectus sets out a more direct response, positioning the organisation as a "tech due diligence engine", with life sciences among its six priority sectors. They want more of the UK's most promising science on home soil rather than watching it scale overseas.
An example of this in action is its Velocity programme. Touted as a “concierge approach to growing innovative businesses”, it will give end-to-end account management for high-potential businesses, bringing funding together with expert support, investor connections and access to the Catapult Network.
Pride of place
It’s a welcome move, however, government support alone won’t be enough to close the gap. Part of the answer must also lie in place.
Because innovation doesn't spark in isolation, it also needs proximity to talent, capital, infrastructure and networks.
Embodying this, Cambridge, London and Oxford’s clusters continue to account for the majority of venture capital directed to UK life sciences. The anchor cities to the Golden Triangle all share the right conditions, in the right location.
CBRE's 2026 Life Sciences Outlook shows strong demand for specialist space in these regions remains. However, the 21 million sq ft development pipeline faces real delivery uncertainty from sticky inflation, rising construction costs and the impact from the war in the Middle East.
Building this space is necessary, but once they are delivered, these new developments will also need to give greater heed to the social impact they can deliver, whether through community wellbeing, local economic stimulation or urban regeneration.
As Pioneer Group's analysis makes clear, when life sciences clusters actively invest in the places they call home, the sector stops feeling like something that happens behind the curtain. It starts to build the kind of local buy-in that sustains long-term growth.
Note: Be sure to watch Pioneer’s video on this in action at Victoria House. It’s superb.
Innovate UK's strategy echoes this inclusive place-shaping approach, with a commitment to work alongside devolved nations, Mayoral Combined Authorities and Local Innovation Partnerships to ensure "the benefits of innovation reach every part of the country."
Closing the gap between scientific leadership and economic impact will require more than policy commitments and planning approvals. What we need is a deliberate approach to building clusters that are inclusive by design, where science, talent, investment and community comes together.
The UK's life science sector remains world class, but it’s not perfect. The hard part is creating the conditions for it to flourish everywhere, not just in the places where we’re already winning.
